Chemotherapy-Induced Acral Erythema Market
The chemotherapy-induced acral erythema market is driven by the rising incidence of cancer, increasing use of chemotherapy drugs, and growing need for effective management of chemotherapy side effects. Increasing awareness and demand for symptomatic relief treatments for hand-foot syndrome remain major drivers of growth in the chemotherapy-induced acral erythema market.